Kazakhstan has launched clinical trials of QazCovid-in – own COVID-19 vaccine, reported TDH last Friday with reference to the Ministry of Education and Science of Kazakhstan.
The Ministry said QazCovid-in vaccine was developed by the Research Institute for Biological Safety Problems of Science Committee of the Ministry of Education and Science (RIBSP).
Clinical trials of the vaccine involve healthy adult volunteers aged 18 to 50 years. The first phase of the study determines the safety of the vaccine. This phase will involve 44 non-infected volunteers with no antibodies. 200 volunteers will participate in the second phase, which aims at testing immunogenicity.
In total, 688 Kazakhstan citizens applied to RIBSP for participation in clinical trials.
Trials will take place at the National Scientific Center of Phthisiopulmonology under the Ministry of Health of Kazakhstan and Center for Clinical Medicine and Research.
